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treated patients, the generic SF-36 and DFS speciﬁc for patients
with foot ulcers. Six other instruments were well validated and
widely used, but their responsiveness was not documented and
their sensitivity to change in RCTs was not consistent across the
trials. CONCLUSIONS: Though several instruments have been
identiﬁed, most of the them are speciﬁc for a subtype of diabetic
population (type 1 or type 2, insulin-treated, patients with com-
plications) and do not meet all criteria in regard to their psy-
chometric properties. Further research is warranted to assess the
sensitivity to change of diabetes speciﬁc patient reported out-
comes instruments.
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OBJECTIVE: Assessment of diabetic patients’ Willingness To
Pay (WTP) for inhaled insulin in relation to injected insulin.
METHODS: A questionnaire concerning preference and WTP
for inhaled insulin was completed by 157 patients (age range,
20–65 years) in Sweden. Type 1 diabetic patients were receiving
treatment with insulin (n = 40) and Type 2 patients were receiv-
ing treatment with either insulin as single therapy (n = 21), a
combination therapy with insulin and anti-diabetic drugs (n =
46), or an oral anti-diabetic treatment with at least 2 oral drugs
(n = 50). Patients were asked to assess their WTP for inhaled
insulin by choosing from eight comparisons, at different prices.
A Conditional Logit model was used to estimate the utility as a
function of treatment and price. The WTP measure were the
incremental price patients were willing to pay for inhaled insulin
compared to injected insulin. RESULTS: Patients were willing to
pay an additional 400SEK [50 US dollars] per month (on
average) for inhaled insulin in comparison to injected insulin.
Type 1 patient reported a lower marginal WTP than Type 2
patients. Type 1 patients were willing to pay an additional 219
SEK. Type 2 patients on insulin as single therapy, or on a com-
bination therapy with insulin and anti-diabetic drugs, or treated
with an oral anti-diabetic treatment with at least 2 oral drugs
were willing to pay additionally 375SEK, 381SEK, 667SEK,
respectively. At equal prices (500SEK) a total of 129 patients
(85%) preferred insulin inhalation. At a large price difference,
(300SEK vs 1400SEK), only 16% preferred inhalations.
However, as many as 27 percent of patients on oral antidiabetic
drug treatment still preferred inhaled insulin. CONCLUSION:
In comparison to injected insulin 85% of patients preferred
inhaled insulin at equal prices and patients are on average willing
to pay 400SEK per month.
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OBJECTIVES: To assess the beneﬁcial and harmful effects of
hepatitis B active immunisation (vaccines) and passive immuni-
sation (immunoglobulins) in newborns of HBsAg-positive
mothers. METHODS: By using the Cochrane Collaboration
methodology we reviewed all randomised trials to assess the ben-
eﬁcial and harmful effects of hepatitis B active immunisation
(vaccines) and passive immunisation (immunoglobulins) for
newborns of positive hepatitis B surface antigen (HBsAg)
mothers. Trials were identiﬁed through the trial registers of 
The Cochrane Hepato-Biliary Group, The Cochrane Neonatal
Group, The Cochrane Library, MEDLINE, EMBASE, authors of
trials, and industry until February 2004. RESULTS: Compared
with placebo/no intervention, hepatitis B immunoglobulins
(HBIG) signiﬁcantly reduced hepatitis B occurrences (RR 0.50,
95% CI 0.41 to 0.60). Compared with vaccination alone, vac-
cination plus HBIG signiﬁcantly reduced hepatitis B occurrences
(RR 0.54, 95% CI 0.41 to 0.73). HBIG signiﬁcantly reduced
hepatitis B occurrences if administered within 12 hours of birth,
but not within 24 or 48 hours of birth. No signiﬁcant difference
on hepatitis B occurrence was found between recombinant
vaccine (RV) or plasma-derived vaccine (PDV) (RR 1.00, 95%
CI 0.71 to 1.42). No signiﬁcant differences on hepatitis B occur-
rences were found between high-dose PDV and low-dose PDV
(RR 0.97, 95% CI 0.55 to 1.68) or high-dose RV and low-dose
RV (RR 0.78, 95% CI 0.31 to 1.94). Hepatitis B vaccines and
HBIG seem generally safe, but few trials reported on adverse
events. In general, methodological quality did not signiﬁcantly
inﬂuence the results. CONCLUSIONS: Hepatitis B vaccination
and HBIG within 12 hours of birth signiﬁcantly reduces hepati-
tis B occurrences in infants of HBsAg-positive mothers.
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OBJECTIVES: To examine dose-response relation of interferon-
a in patients with HBeAg positive chronic hepatitis B (CHB) and
quantify the effect size of treatment in different regimens.
METHODS: We searched Medline, SCI-expanded, Current
Content Connect, Cochrane Library, and Chinese Biomedical
Database to September 2005, and screened references of eligible
studies. Randomized trials comparing interferon-a with non-
antiviral interventions (placebo/no treatment/standard care) in
patients with HBeAg-positive CHB were included. Heterogene-
ity was examined by the Q statistics and Galbraith plots. 
Meta-regression was used to analyze the relation of study char-
acteristics to treatment outcomes. Fixed and random effect meta-
analysis were used to pooled virological and serological
response. When results differed in two models, random effect
model was reported. RESULTS: Thirty-two trials were included
(n = 2164). Dose of interferon-ranged from 1–10MU, treatment
duration ranged from 4–24 weeks, and length of follow-up
varied from 12–130 weeks. Loss of HBeAg was responsive to
dose (coefﬁcient = 0.156, 95% CI = 0.028–0.28) and duration
(coefﬁcient = 0.076, 95%CI = 0.0048–0.15), while other out-
comes were not. Stratiﬁed analyses showed that high-dose (≥5
MU) and regular duration (16–24 weeks) could effectively clear
HBeAg (OR = 3.28, 95% CI = 2.31–4.66; OR = 3.28, 95% CI
= 2.16–5.00), and clear HBV DNA (OR = 2.80, 95% CI =
2.03–3.86; OR = 2.58, 95% CI = 1.62–4.12). HBeAg serocon-
version could be seen in all-dose groups (OR = 2.02, 95% CI =
1.37–2.97). The number-needed-to-treat for loss of HBeAg was
four in high-dose and nine in low-dose treatment. Speciﬁcally, a
high-dose and regular-duration of interferon-Á was associated
with signiﬁcantly higher loss of HBeAg in Chinese patients (OR
= 2.99, 95% CI = 1.53–5.87; OR = 2.56, 95% CI = 1.23–5.33),
which otherwise was not effective in clearing HBV DNA. CON-
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CLUSIONS: Loss of HBeAg is responsive to dose and duration
in the treatment with interferon-a. A high-dose (≥5MU) and
regular-duration (16–24 weeks) interferon-a is effective than in
clearing virological and serological markers. A dose ≥5MU and
a duration 16–24 week interferon-a is recommended to use.
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OBJECTIVES: The gastrointestinal (GI) risks associated with
selective cyclooxygenase-2 inhibitors (COX-2s) versus non-
selective non-steroidal anti-inﬂammatory drugs (NSAIDs)
among arthritis patients are well documented in clinical trials.
This study is to estimate the major GI risks among elderly
chronic users of COX-2s versus NSAIDs, with/without aspirin
(ASA), in clinical practice. METHODS: A cohort study was con-
ducted using secondary data from the GE logician database
(Centricity EMR), which contained medical records of 3 million
patients seen by 5,000 physicians across 27 states. Inclusion cri-
teria: chronic use (2 or more medication mentions) of COX-2s
or NSAIDs within 60 days between 1/1/1999 and 6/30/2003, 65
or older, no switch between COX-2s and NSAIDs during one-
year follow-up or before a major GI event, deﬁned as GI hem-
orrhage including melena (ICD-9 codes: 578.xx). Descriptive
and multivariate logistic analyses were conducted to determine
how major GI risks differed across chronic users of COX-2s
alone, NSAIDs alone, COX-2s + ASA, and NSAIDs + ASA. The
logistic analysis controlled for gender, age, pre- or post-index GI-
harmful drug use, major and minor GI events in the year prior
to index date, and prior GI-protective drug use. RESULTS: The
number of patients and the percent having major GI events
during one-year follow-up period were as follows: COX-2s-
alone 7,338 (1.73%); NSAIDs-alone 3,826 (2.06%); COX-2s +
ASA 963 (1.77%); and NSAIDs + ASA 602 (2.66%). The mul-
tivariate logistic results showed that compared to COX-2s-alone
users, NSAIDs-alone and NSAIDs + ASA users had higher major
GI risks (OR = 1.35, p = 0.04, 95% CI: 1.01–1.80; and OR =
1.68, p = 0.06, 95% CI: 0.99–2.86 respectively). COX-2s + ASA
users had similar risks (OR = 0.96, p = 0.88, 95% CI: 0.57–1.61)
to COX-2s-alone users. CONCLUSIONS: The major GI risk
was highest among elderly chronic users of NSAIDs + ASA, fol-
lowed by NSAIDs-alone. Only NSAIDs-alone users had a statis-
tically signiﬁcant higher risk than COX-2s-alone users. The
addition of ASA did not signiﬁcantly increase major GI risk
among COX-2 users.
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OBJECTIVES: Few trials directly compared lamivudine with
adefovir in patients with HBeAg-positive and HBeAg-negative
chronic hepatitis B (CHB). This study used direct and indirect
comparison methods to compare the relative efﬁcacy of lamivu-
dine to adefovir. METHODS: We searched Medline, SCI-
expanded, Current Content Connect, Cochrane Library and
Chinese Biomedical Database to September 15, 2005, and man-
ually screened the references of included studies. Trials for
HBeAg-positive and HBeAg-negative CHB were included if they
directly compared lamivudine with adefovir, or compared
lamivudine (or adefovir) with placebo/non-treatment. Direct
comparison was made by pooling the trials of lamivudine versus
adefovir. An adjusted indirect comparison was performed by 
calculating the difference of pooled estimates of lamivudine and
adefovir, which was obtained from trials of lamivudine (or 
adefovir) versus placebo/no treatment. RESULTS: Eight trials 
(n = 1324) were included. Of these, six were trials for HBeAg-
positive CHB patients, and two for HBeAg-negative CHB
patients. One trial compared lamivudine with adefovir in lamivu-
dine-resistant patients with HBeAg-positive CHB, and seven
trials compared lamivudine (or adefovir) with placebo/non-treat-
ment in naïve patients. Quality was medium-to-high in most
trials. The direct comparison for lamivudine-resistant patients
showed that lamivudine with adefovir were equivalent in clear-
ing serological markers, lamivudine was less effective in nor-
malizing ALT (OR = 0.11, 95%CI = 0.013–0.97) but superior
in histological response (OR = 2.08, 95%CI = 1.08–4.04). Indi-
rect comparison from four trials (n = 915) showed that lamivu-
dine and adefovir were equally effective in serological and
biomedical markers in naïve patients with HBeAg-positive CHB.
Indirect comparison from two trials (n = 282) showed that
lamivudine was more effective in normalization of ALT than 
adefovir in HBeAg-negative CHB. But no data on serological and
histological response were available. CONCLUSION: Lamivu-
dine and adefovir was equally effective for naïve patients with
HBeAg-positive CHB. Larger direct comparison trials for
lamivudine-resistant CHB and HBeAg-negative CHB should be
further performed.
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OBJECTIVES: The interferons (IFNs) currently indicated for the
treatment of chronic Hepatitis C Virus (HCV) have been shown
to exhibit varying responsiveness in terms of achieving a sus-
tained viral response (SVR). It is the objective of this model to
be used as tool to compare the relative cost-effectiveness of these
agents from a payer perspective. METHODS: An interactive
Excel-based model was developed to compare the relative cost
of treating chronic HCV in terms of both treatment naïve and
pegylated-IFN nonresponders. Drug effectiveness with respect to
the SVR rate was based on the published literature for therapy
in combination with weight-based ribavirin. Drug costs were
based on average wholesale price cost with consideration of con-
tractual discounts and patient co-payment. The primary eco-
nomic endpoint was the drug cost per SVR obtained. Results
were displayed for treatment naïve, pegylated-IFN nonrespon-
ders, and combined cases respectively. Multi-factor sensitivity
analyses were conducted. RESULTS: In a typical managed care
population, with an estimated prevalence of chronic HCV of
1.4% and with 5% of patients being treated, the drug cost of
HCV treatment is $1.22 PMPM. For treatment naïve patients,
Genotype I, the cost per SVR obtained is $31,356, $51,152, and
$19,113 for Pegasys, Peg-Intron, and consensus interferon
(CIFN) respectively. For treatment naïve patients, Genotypes 2/3,
the cost per SVR obtained is $18,030, $24,890, and $12,305 for
